Monitoring of erlotinib plasma concentrations after long time administration of 100 mg in advanced pancreatic cancer patients

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter A. Sahmanovic
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors A. Sahmanovic1, P. Buchner1, M. Lichtneckert2, C. Dittrich2, A. Farkouh1, A. Gruber1, N. Baroian1, M. Kitzmueller1, M. Czejka1
  • 1Department of Clinical Pharmacy and Diagnostics, University of Vienna, Vienna, Austria, /
  • 2Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna), Kaiser Franz Josef-Spital, 3rd Medical Department – Centre for Oncology and Haematology, Vienna, Austria, /


Erlotinib selectively inhibits the intracellular phosphorylation of human EGFR-Type 1, expressed on the cell surface of normal and cancer cells, thus preventing the signal transduction and resulting in an inhibition of angiogenesis which prevents proliferation, invasion and migration of tumor cells. To date only few data have been reported about the plasma disposition of erlotinib during long time administration. We report the monitoring of erlotinib plasma concentration in 14 patients when given daily 100 mg together with other various drugs up to 60 weeks. The objective was to assess the steady-state pharmacokinetics and Ctrough of erlotinib over a long time period and to evaluate variability of plasma concentrations when combined with other drugs.